Literature DB >> 18765304

Mitotic delay in lymphocytes from BRCA1 heterozygotes unable to reduce the radiation-induced chromosomal damage.

Emma Febrer1, Marta Mestres, María Rosa Caballín, Leonardo Barrios, Montserrat Ribas, Sara Gutiérrez-Enríquez, Carmen Alonso, Teresa Ramón y Cajal, Joan Francesc Barquinero.   

Abstract

Double strand breaks (DSB) are critical lesions involved in the formation of chromosomal aberrations. In response to DNA damage, the cell has mechanisms of repair and cell-cycle control to maintain the genome integrity in which BRCA1 gene is implicated. In the present study an evaluation of the radio-induced damage in G(2) phase of the cell cycle in lymphocytes from BRCA1 heterozygotes is presented. For this purpose Calyculin-A-based premature chromosome condensation (PCC) combined with mitotic arrest has been applied to examine with conventional cytogenetics the damage in G(2) and M phase cells, and to evaluate the G(2)-to-M phase transition. Irradiated peripheral blood lymphocytes from seven heterozygote females (BRCA1(+/-)) and seven control females (BRCA1(+/+)) have been analyzed. The mean proportion of G(2) cells in BRCA1(+/-) was significantly higher than in BRCA1(+/+), indicating a higher G(2) delay after IR exposure in cells from BRCA1(+/-) females. On the other hand, whereas the mean frequency of chromatid breaks (chtb) in G(2) cells was not statistically different between both groups, the mean frequency of chtb in M cells of the BRCA1(+/-) group was significantly higher than in the BRCA1(+/+) one. Moreover, the mean proportion of M cells with aberrations was significantly higher in BRCA1(+/-) than in BRCA1(+/+) suggesting that in spite of the higher G(2) delay of BRCA1(+/-) more damaged cells are able to pass the G(2)-to-M transition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765304     DOI: 10.1016/j.dnarep.2008.08.001

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  7 in total

1.  G2 checkpoint control and G2 chromosomal radiosensitivity in cancer survivors and their families.

Authors:  Kevin K Cadwell; Gillian B Curwen; E Janet Tawn; Jeanette F Winther; John D Boice
Journal:  Mutagenesis       Date:  2010-11-02       Impact factor: 3.000

Review 2.  Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.

Authors:  Alexis Vallard; Nicolas Magné; Jean-Baptiste Guy; Sophie Espenel; Chloé Rancoule; Peng Diao; Eric Deutsch; Sofia Rivera; Cyrus Chargari
Journal:  Br J Radiol       Date:  2019-02-27       Impact factor: 3.039

3.  Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

Authors:  David G Cox; Jacques Simard; Daniel Sinnett; Yosr Hamdi; Penny Soucy; Manon Ouimet; Laure Barjhoux; Carole Verny-Pierre; Lesley McGuffog; Sue Healey; Csilla Szabo; Mark H Greene; Phuong L Mai; Irene L Andrulis; Mads Thomassen; Anne-Marie Gerdes; Maria A Caligo; Eitan Friedman; Yael Laitman; Bella Kaufman; Shani S Paluch; Åke Borg; Per Karlsson; Marie Stenmark Askmalm; Gisela Barbany Bustinza; Katherine L Nathanson; Susan M Domchek; Timothy R Rebbeck; Javier Benítez; Ute Hamann; Matti A Rookus; Ans M W van den Ouweland; Margreet G E M Ausems; Cora M Aalfs; Christi J van Asperen; Peter Devilee; Hans J J P Gille; Susan Peock; Debra Frost; D Gareth Evans; Ros Eeles; Louise Izatt; Julian Adlard; Joan Paterson; Jacqueline Eason; Andrew K Godwin; Marie-Alice Remon; Virginie Moncoutier; Marion Gauthier-Villars; Christine Lasset; Sophie Giraud; Agnès Hardouin; Pascaline Berthet; Hagay Sobol; François Eisinger; Brigitte Bressac de Paillerets; Olivier Caron; Capucine Delnatte; David Goldgar; Alex Miron; Hilmi Ozcelik; Saundra Buys; Melissa C Southey; Mary Beth Terry; Christian F Singer; Anne-Catharina Dressler; Muy-Kheng Tea; Thomas V O Hansen; Oskar Johannsson; Marion Piedmonte; Gustavo C Rodriguez; Jack B Basil; Stephanie Blank; Amanda E Toland; Marco Montagna; Claudine Isaacs; Ignacio Blanco; Simon A Gayther; Kirsten B Moysich; Rita K Schmutzler; Barbara Wappenschmidt; Christoph Engel; Alfons Meindl; Nina Ditsch; Norbert Arnold; Dieter Niederacher; Christian Sutter; Dorothea Gadzicki; Britta Fiebig; Trinidad Caldes; Rachel Laframboise; Heli Nevanlinna; Xiaoqing Chen; Jonathan Beesley; Amanda B Spurdle; Susan L Neuhausen; Yuan C Ding; Fergus J Couch; Xianshu Wang; Paolo Peterlongo; Siranoush Manoukian; Loris Bernard; Paolo Radice; Douglas F Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Dominique Stoppa-Lyonnet; Sylvie Mazoyer; Olga M Sinilnikova
Journal:  Hum Mol Genet       Date:  2011-09-02       Impact factor: 6.150

4.  Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation.

Authors:  Bhavana V Chapman; Diane Liu; Yu Shen; Oluwafikayo O Olamigoke; David S Lakomy; Angelica M Gutierrez Barrera; Shane R Stecklein; Gabriel O Sawakuchi; Scott J Bright; Isabelle Bedrosian; Jennifer K Litton; Benjamin D Smith; Wendy A Woodward; George H Perkins; Karen E Hoffman; Michael C Stauder; Eric A Strom; Banu K Arun; Simona F Shaitelman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-10-03       Impact factor: 8.013

5.  Differences in DNA Repair Capacity, Cell Death and Transcriptional Response after Irradiation between a Radiosensitive and a Radioresistant Cell Line.

Authors:  Mireia Borràs-Fresneda; Joan-Francesc Barquinero; Maria Gomolka; Sabine Hornhardt; Ute Rössler; Gemma Armengol; Leonardo Barrios
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

6.  Assessment of genotoxic potential of arsenic in female albino rats at permissible dose levels.

Authors:  Madhuri Mehta; Swarndeep Singh Hundal
Journal:  Toxicol Int       Date:  2014-01

7.  Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.

Authors:  Annelot Baert; Julie Depuydt; Tom Van Maerken; Bruce Poppe; Fransiska Malfait; Katrien Storm; Jenneke van den Ende; Tim Van Damme; Sylvia De Nobele; Gianpaolo Perletti; Kim De Leeneer; Kathleen B M Claes; Anne Vral
Journal:  Breast Cancer Res       Date:  2016-05-17       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.